Abstract

Alzheimer’s disease (AD) lies in the category of those diseases which are still posing challenges to medicinal chemists, and the search for super-effective drugs for the treatment of AD is a work in progress. The inhibition of cholinesterase is considered a viable strategy to enhance the level of acetylcholine in the brain. The C-5 substituted derivative of Meldrum’s acid was synthesized and screened against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzyme inhibition activity. The simple and unique structure of synthesized derivative 3 was found to be good for the dual inhibition of both enzymes (AChE and BChE). 2,2-Dimethyl-5-(([2-(trifluoromethyl) phenyl]amino)methylidene)-1,3-dioxane-4,6-dione (3) showed significant inhibition against AChE, with an IC50 value of 1.13 ± 0.03 µ M (Standard Neostigmine 22.2 ± 3.2 µM), and moderate inhibition against BChE, with an IC50 value of 2.12 ± 1.22 µM (Standard Neostigmine 49.6 ± 6.11 µM). The structural insights reveal that compound 3 possesses intriguing reactive groups, which can potentially evoke the non-covalent interactions and possibly assist by binding in the active site of the target protein. Docking simulations revealed that the compound 3 showed binding inside the active site gorges of both AChE and BChE. An excellent agreement was obtained, as the best docked poses showed important binding features mostly based on interactions due to oxygen atoms and the aromatic moieties of the compound. The docking computations coupled with the experimental findings ascertained that the compound 3 can serve as a scaffold for the dual inhibitors of the human acetylcholine esterases.

Highlights

  • Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the loss of memory and consciousness

  • Various classes of compounds have been reported as potent inhibitors of chloninesterase, including organophosphates, coumarin and cinnamide, acyl thioureas, acridones, chalcones, 2,3-dihydroquinazolin-4(1H)-one, polyamine ligands, acrylonitriles, morpholine derivatives, 2H-2-chromenones, and tetracyclic terpenes [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25]

  • The carbon magnetic resonance spectra were recorded in DMSO-d6 with an Advance AV 300 spectrometer and an Advance AV 500 spectrometer operating at 300 MHz and 500 MHz, respectively

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the loss of memory and consciousness. A cholinergic hypothesis is the sole guideline to resolve the loss of acetylcholine, a vital neurotransmitter which helps in the communication of nerve and motor cells. A decline in the level of acetylcholine causes impairment in the cognitive functions of the human brain. Despite having moderate success rate in the cure of AD, these prescribed drugs suffer from adverse effects such as nausea and diarrhea. To develop effective acetylcholinesterase inhibitors (AChEI), the activity of acetylcholinesterase (AChE) must be inhibited at the oxyanion hole site (AS) and peripheral anionic site (PAS), because binding AChE at PAS results in the accumulation of amyloid-β peptide plaques. To improve the drug to function effectively, inhibitors must bind at PAS in order to impede the function of AChE. Various classes of compounds have been reported as potent inhibitors of chloninesterase, including organophosphates, coumarin and cinnamide, acyl thioureas, acridones, chalcones, 2,3-dihydroquinazolin-4(1H)-one, polyamine ligands, acrylonitriles, morpholine derivatives, 2H-2-chromenones, and tetracyclic terpenes [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call